HealthDay News — Relaxation and stress management techniques have short-term beneficial effects for people with hypertension, according to a systematic review and network meta-analysis published ...

To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A retrospective analysis from Israel suggested that markers of poor hydration are linked to increased risks of hypertension and heart failure. ( European Journal of Preventive Cardiology) ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Although several Group 1 PH (Pulmonary Arterial Hypertension, “PAH”) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About Tectonic Tectonic ...

The new analysis, they note, further verifies that while the use of either e-cigarettes or traditional “combustible” ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...